Cabenuva is a long acting HIV treatment option that combines cabotegravir and rilpivirine. Unlike daily oral HIV medicines, it is administered as injections at scheduled intervals by a healthcare professional. Eligibility depends on several factors, including whether a person has achieved and maintained viral suppression, their treatment history, and whether there are concerns about resistance to either medicine. Understanding Cabenuva eligibility can help people discuss appropriate treatment choices with their healthcare provider. This article explains how Cabenuva works, who may be considered for therapy, important treatment requirements.
Cabenuva is a long acting HIV treatment that combines two antiretroviral medicines, cabotegravir and rilpivirine. It provides an alternative to taking HIV medicines orally every day. The treatment is administered through injections by a healthcare professional according to a scheduled dosing plan. Cabenuva is generally considered for certain adults and adolescents whose HIV is already controlled with antiretroviral therapy. Understanding eligibility requirements is important because long acting treatment is not appropriate for everyone. Healthcare professionals consider viral suppression, treatment history, resistance, other medications, and individual circumstances before recommending this approach.
Cabenuva eligibility is based on clinical factors that help determine whether the treatment can maintain effective control of HIV. A person generally needs to have stable viral suppression and no history of treatment failure associated with resistance to cabotegravir or rilpivirine. Before switching to injections, a healthcare provider reviews the person's HIV treatment history and may assess previous laboratory results.
Important considerations may include:
Maintaining an undetectable or suppressed HIV viral load on the current treatment.
Having no known or suspected resistance to cabotegravir or rilpivirine.
Having no active hepatitis B infection that requires treatment with medicines included in the current HIV regimen.
Reviewing other medicines and supplements for possible drug interactions.
Considering previous HIV treatment experiences and adherence.
Confirming that regular injection appointments are practical and appropriate.
Cabenuva may involve an initial oral medication period in some treatment plans before injections are continued. The exact approach depends on the healthcare provider's assessment and the approved treatment schedule.
Long acting HIV therapy changes how antiretroviral treatment is delivered. Instead of taking HIV medication every day, eligible individuals receive injections at healthcare appointments. This can reduce the need to remember daily tablets, although keeping scheduled appointments remains important. Missing injections can result in drug levels becoming too low, potentially increasing the risk of treatment failure and drug resistance.
People considering Cabenuva should discuss several practical and medical factors with their healthcare provider:
The recommended injection schedule and appointment requirements.
Possible injection site reactions such as pain, swelling, or discomfort.
Other potential adverse effects and how they may be managed.
The importance of attending appointments on schedule.
What to do if an injection appointment is delayed or missed.
Whether other medicines could interact with cabotegravir or rilpivirine.
Whether another HIV treatment would be more appropriate based on individual circumstances.
Long acting treatment does not cure HIV. Like other effective antiretroviral therapies, it is intended to suppress HIV replication and help maintain viral control when used as prescribed. Regular medical monitoring remains important to evaluate viral load, treatment response, and overall health.
Cabenuva eligibility and treatment decisions should therefore be individualized. A healthcare professional can review laboratory results, medical history, current medicines, and previous HIV treatments before determining whether this therapy is suitable.
Cabenuva offers a long acting approach to HIV treatment for people who meet specific eligibility requirements. Its injection-based schedule can provide an alternative to daily oral therapy, but successful treatment depends on appropriate patient selection, regular medical monitoring, and timely administration. Anyone considering a change in HIV treatment should discuss the potential benefits, risks, eligibility requirements, and practical considerations with a qualified healthcare professional.